Enfortumab vedotin and pembrolizumab with surgery significantly improve outcomes in cisplatin-ineligible MIBC patients, ...
Pfizer and Japanese firm Astellas' drug Padcev, combined with Merck's Keytruda, lowered the risk of tumor recurrence, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback